ערך בספרים למניה: SELLAS Life Sciences Group, Inc. (SLS)

This chart shows the market price of SELLAS Life Sciences (SLS) on the GURU.Markets platform at 0.68. The company's operations are protected by global humanitarian law and remain independent of sanctions. The business focuses on the commercialization of myeloid leukemia therapy through successful clinical trials. The uniqueness of the approach lies in GPS technology, which trains the immune system to recognize the WT1 protein to combat relapses.

Professional managers utilize fundamental filters to assess the actual volume of equity available per share of business after deducting all liabilities. This calculation logic, reflected in the book value per share, allows for an assessment of the intrinsic value of SELLAS Life Sciences (SLS), whose capitalization is supported by the retention of key immunologists through option programs and the advancement of its vaccine pipeline.